20 Takeover Rumors Hedge Funds Are Buying

Page 12 of 18

7. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

No. of Hedge Funds: 51

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology firm located in California. The firm’s focus is on rare genetic disorders. The company’s product portfolio includes therapies for phenylketonuria, mucopolysaccharidosis, and hemophilia. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) sets itself apart from competitors like Alexion through first-mover advantages and regulatory expertise in orphan drugs. Their pipeline, including gene therapy assets, extends their leadership in rare disease treatment through innovation.

The company has been a regular target of potential takeovers since 2013. In December 2023, Jean-Jacques Bienaimé stepped down from his position as the company CEO, and Alexander Hardy took over. The replacement itself sparked takeover rumors since such changes are expected to signal a potential strategic shift. In the first quarter of 2024, analysts had estimated a possible takeover with a value ranging between $130 and $150 per share. The estimation was primarily based on anticipating Voxzogo and Roctavian’s key drugs achieving substantial sales. This estimation of takeover is renewed in 2025, with the company expecting continued growth driven by Voxzogo and other therapies.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is currently backed by 51 hedge funds, thus demonstrating strong institutional confidence in the stock. Supported by positive results in 2024, takeover speculation might also boost investor interest.

Page 12 of 18